share_log

Altimmune | 10-Q: Q3 2024 Earnings Report

Altimmune | 10-Q: Q3 2024 Earnings Report

Altimmune | 10-Q：2024财年三季报
美股SEC公告 ·  2024/11/13 05:13

Moomoo AI 已提取核心信息

Altimmune reported a net loss of $22.8 million for Q3 2024, compared to $20.7 million in Q3 2023, with total revenue declining to $5,000 from $362,000. Research and development expenses increased 8% to $19.8 million, primarily driven by the advancement of pemvidutide clinical trials. The company ended the quarter with $139.4 million in cash and investments.The company achieved significant progress with pemvidutide, completing enrollment in the Phase 2b IMPACT trial for MASH treatment, with top-line data expected in Q2 2025. Additionally, Altimmune successfully concluded its End-of-Phase 2 Meeting with the FDA, reaching agreement on the design of Phase 3 registrational program for obesity treatment, which will include four trials enrolling approximately 5,000 subjects.Management maintains that current cash reserves are sufficient to fund operations for at least 12 months. The company continues to focus on developing treatments for obesity and liver diseases, with pemvidutide showing promising results in body composition analysis, including 78.1% of weight loss derived from adipose tissue and only 21.9% from lean mass in the MOMENTUM Phase 2 obesity trial.
Altimmune reported a net loss of $22.8 million for Q3 2024, compared to $20.7 million in Q3 2023, with total revenue declining to $5,000 from $362,000. Research and development expenses increased 8% to $19.8 million, primarily driven by the advancement of pemvidutide clinical trials. The company ended the quarter with $139.4 million in cash and investments.The company achieved significant progress with pemvidutide, completing enrollment in the Phase 2b IMPACT trial for MASH treatment, with top-line data expected in Q2 2025. Additionally, Altimmune successfully concluded its End-of-Phase 2 Meeting with the FDA, reaching agreement on the design of Phase 3 registrational program for obesity treatment, which will include four trials enrolling approximately 5,000 subjects.Management maintains that current cash reserves are sufficient to fund operations for at least 12 months. The company continues to focus on developing treatments for obesity and liver diseases, with pemvidutide showing promising results in body composition analysis, including 78.1% of weight loss derived from adipose tissue and only 21.9% from lean mass in the MOMENTUM Phase 2 obesity trial.
Altimmune在2024年第三季度报告的净亏损为2280万美元，而2023年第三季度为2070万美元，总营业收入从362,000下降至5,000美元。研发支出增加8%，达到1980万美元，主要是由于pemvidutide临床试验的推进。公司在本季度末拥有现金和投资13940万美元。该公司在pemvidutide方面取得了重要进展，完成了MASH治疗的20亿IMPACt试验的入组，预计将在2025年第二季度获得最终数据。此外，Altimmune成功结束了与FDA的二期结束会议，就肥胖治疗的三期注册项目设计达成一致，该项目将包括四个试验，招募约5,000名受试者。管理层认为目前的现金储备足以支持至少12个月的运营。公司继续专注于开发肥胖和肝病的治疗，pemvidutide在身体成分分析中显示出有希望的结果，包括在MOMENTUm二期肥胖试验中，78.1%的体重减轻来自脂肪组织，仅21.9%来自瘦体重。
Altimmune在2024年第三季度报告的净亏损为2280万美元，而2023年第三季度为2070万美元，总营业收入从362,000下降至5,000美元。研发支出增加8%，达到1980万美元，主要是由于pemvidutide临床试验的推进。公司在本季度末拥有现金和投资13940万美元。该公司在pemvidutide方面取得了重要进展，完成了MASH治疗的20亿IMPACt试验的入组，预计将在2025年第二季度获得最终数据。此外，Altimmune成功结束了与FDA的二期结束会议，就肥胖治疗的三期注册项目设计达成一致，该项目将包括四个试验，招募约5,000名受试者。管理层认为目前的现金储备足以支持至少12个月的运营。公司继续专注于开发肥胖和肝病的治疗，pemvidutide在身体成分分析中显示出有希望的结果，包括在MOMENTUm二期肥胖试验中，78.1%的体重减轻来自脂肪组织，仅21.9%来自瘦体重。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Forte Biosciences
    FBRX
    -- 8.510
    Plus Therapeutics
    PSTV
    -- 1.4300
    IO Biotech
    IOBT
    -- 1.170
    Celularity
    CELU
    -- 2.1500
    Tiziana Life Sciences
    TLSA
    -- 1.2300
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点